Correlation Between Eli Lilly and Cardiol Therapeutics
Can any of the company-specific risk be diversified away by investing in both Eli Lilly and Cardiol Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eli Lilly and Cardiol Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eli Lilly and and Cardiol Therapeutics Class, you can compare the effects of market volatilities on Eli Lilly and Cardiol Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eli Lilly with a short position of Cardiol Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eli Lilly and Cardiol Therapeutics.
Diversification Opportunities for Eli Lilly and Cardiol Therapeutics
0.61 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Eli and Cardiol is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Eli Lilly and and Cardiol Therapeutics Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiol Therapeutics and Eli Lilly is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eli Lilly and are associated (or correlated) with Cardiol Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiol Therapeutics has no effect on the direction of Eli Lilly i.e., Eli Lilly and Cardiol Therapeutics go up and down completely randomly.
Pair Corralation between Eli Lilly and Cardiol Therapeutics
Considering the 90-day investment horizon Eli Lilly and is expected to generate 0.61 times more return on investment than Cardiol Therapeutics. However, Eli Lilly and is 1.65 times less risky than Cardiol Therapeutics. It trades about -0.1 of its potential returns per unit of risk. Cardiol Therapeutics Class is currently generating about -0.12 per unit of risk. If you would invest 89,691 in Eli Lilly and on October 7, 2024 and sell it today you would lose (11,493) from holding Eli Lilly and or give up 12.81% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Eli Lilly and vs. Cardiol Therapeutics Class
Performance |
Timeline |
Eli Lilly |
Cardiol Therapeutics |
Eli Lilly and Cardiol Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Eli Lilly and Cardiol Therapeutics
The main advantage of trading using opposite Eli Lilly and Cardiol Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eli Lilly position performs unexpectedly, Cardiol Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will offset losses from the drop in Cardiol Therapeutics' long position.Eli Lilly vs. Johnson Johnson | Eli Lilly vs. Bristol Myers Squibb | Eli Lilly vs. AbbVie Inc | Eli Lilly vs. Pfizer Inc |
Cardiol Therapeutics vs. Flora Growth Corp | Cardiol Therapeutics vs. ABVC Biopharma | Cardiol Therapeutics vs. Indaptus Therapeutics | Cardiol Therapeutics vs. HCW Biologics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Complementary Tools
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |